Migraine and Headache
Migraine with aura is associated with an elevated risk for incident atrial fibrillation.
Hemicrania continua, one of the trigeminal primary headaches, causes intense unilateral pain for ≥3 months.
Psychological factors such as attitudes, beliefs, and motivation level may affect adherence with nonpharmacologic therapies for headaches.
Vitamin D3 may reduce migraine days in patients who experience frequent migraines.
Positive topline results were announced from a Phase 3 trial evaluating the safety and efficacy of rimegepant Zydis orally dissolving tablet for the acute treatment of migraine.
Investigators examined the characteristics of prolonged auras associated with migraines.
Pregnant women presenting with migraine to acute care settings were found to be treated with therapeutic agents ranging from safe and effective medications to others with unclear efficacy and potential teratogenicity.
The FDA clearance was based on data from 2 studies.
Researchers identified similar characteristics in adolescent girls who experience frequent headaches.
The use of the HEADWORK questionnaire may provide insight into the effects of migraines on work productivity and lost workdays.
A review of patients' medical charts was performed to determine characteristics of headache in pseudotumor cerebri syndrome in adolescents.
The investigators sought to evaluate the prevalence of migraines, as well as the effect of sex and stress on migraines.
The NDA submission included data from two Phase 3 trials, SAMURAI and SPARTAN.
The analysis revealed that oversimplifications led to the misconception of jolt accentuation of headache as a stand-alone, universal indicator of acute meningitis.
A study looked at use of IV fluids, ketorolac, dexamethasone, and DRAs prochlorperazine/metoclopramide from 1999-2000 to 2014 in the treatment of patients with migraine admitted to the ED.
Researchers and pain experts formulated guidelines for the use of onabotulinumtoxinA for the management of chronic migraine.
Abnormal sleep latency and impaired function related to concentration issues may occur more frequently in patients with chronic vs episodic migraine.
Recommendations on the use of these agents in this patient population were published in a Views and Perspectives paper in the journal Headache.
Compared with patients not reporting headache, patients with HRH had significantly greater differences in pre- and post-BUN values.
A significantly lower percentage of patients receiving a 70-mg or 140-mg dose of erenumab had severe disability during treatment compared with placebo.
The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine.
Fremanezumab treatment may be efficacious in reducing the number of monthly headache days in the long-term in people with chronic migraine.
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
Few patients were found to take triptan medications to treat acute migraine, and a majority of those who had, discontinued the treatment due to side effects.
Lasmiditan was found to be more effective compared with placebo in eliminating pain and other symptoms associated with headache in individuals with migraine.
Investigator analyzed the number of scripts and days of therapy in patients with migraine to determine use and frequency of overuse.
Fremanezumab may be efficacious for the prophylaxis of chronic migraine in individuals with comorbid migraine and moderate/moderate to severe depression.
DFN-11, a 3 mg subcutaneous sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine.
People with migraines and comorbid mood disorders often need treatments that address both conditions, as well as management of sleep, stress, and lifestyle issues.
Patients with migraine headaches—particularly those accompanied by aura—may be at significantly increased risk for 30-day hospital readmission because of pain after surgery.
Neurology Advisor Articles
- Surgical, Nonsurgical Treatments for Chronic Migraine: Evidence and Relevancy
- Rituximab Effects in Neuromyelitis Optica Spectrum Disorders
- Neurofilament Light Biomarkers Identify Alzheimer Disease Risk in Down Syndrome
- Myoclonic-Atonic Seizures and Lennox-Gastaut Syndrome Present With Overlapping Features, Difficulty in Diagnosis
- Tap Water in Neti Pot Linked to Brain Infection, Death From Balamuthia mandrillaris
- Navigating Social Media Issues in Medical Practice: An Expert Interview
- High Plasma NFL Linked to Poor Cognition in Alzheimer and Parkinson Disease
- Most Insured Patients Not Using Online Portals
- Ultrarestrictive Opioid Rx Protocol Cuts Postoperative Opioid Use
- Concussion Linked to High Suicide Risk in a Systematic Review and Meta-Analysis